Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 519

1.

Smart delivery of vaccines.

Melief CJM.

Nat Mater. 2018 Jun;17(6):482-483. doi: 10.1038/s41563-018-0085-6. No abstract available.

PMID:
29795220
2.

Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System.

Fletcher EAK, van Maren W, Cordfunke R, Dinkelaar J, Codee JDC, van der Marel G, Melief CJM, Ossendorp F, Drijfhout JW, Mangsbo SM.

J Immunol. 2018 Jul 1;201(1):87-97. doi: 10.4049/jimmunol.1700911. Epub 2018 May 11.

PMID:
29752315
3.

Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial.

Teulings HE, Tjin EPM, Willemsen KJ, van der Kleij S, Ter Meulen S, Kemp EH, Krebbers G, van Noesel CJM, Franken CLMC, Drijfhout JW, Melief CJM, Nieuweboer-Krobotova L, Nieweg OE, van der Hage JA, van der Veen JPW, Relyveld GN, Luiten RM.

Oncoimmunology. 2018 Jan 15;7(4):e1419113. doi: 10.1080/2162402X.2017.1419113. eCollection 2018.

4.

HBV-Derived Synthetic Long Peptide Can Boost CD4+ and CD8+ T-Cell Responses in Chronic HBV Patients Ex Vivo.

Dou Y, van Montfoort N, van den Bosch A, de Man RA, Zom GG, Krebber WJ, Melief CJM, Buschow SI, Woltman AM.

J Infect Dis. 2018 Feb 14;217(5):827-839. doi: 10.1093/infdis/jix614.

5.

Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses.

Mangsbo SM, Fletcher EAK, van Maren WWC, Redeker A, Cordfunke RA, Dillmann I, Dinkelaar J, Ouchaou K, Codee JDC, van der Marel GA, Hoogerhout P, Melief CJM, Ossendorp F, Drijfhout JW.

Mol Immunol. 2018 Jan;93:115-124. doi: 10.1016/j.molimm.2017.11.004. Epub 2017 Nov 22.

PMID:
29175591
6.

Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance.

Bloy N, Garcia P, Laumont CM, Pitt JM, Sistigu A, Stoll G, Yamazaki T, Bonneil E, Buqué A, Humeau J, Drijfhout JW, Meurice G, Walter S, Fritsche J, Weinschenk T, Rammensee HG, Melief C, Thibault P, Perreault C, Pol J, Zitvogel L, Senovilla L, Kroemer G.

Immunol Rev. 2017 Nov;280(1):165-174. doi: 10.1111/imr.12582. Review.

PMID:
29027230
7.

Cancer: Precision T-cell therapy targets tumours.

Melief CJM.

Nature. 2017 Jul 13;547(7662):165-167. doi: 10.1038/nature23093. Epub 2017 Jul 5. No abstract available.

PMID:
28678783
8.

Novel insights into the HLA class I immunopeptidome and T-cell immunosurveillance.

Melief CJM, Kessler JH.

Genome Med. 2017 May 24;9(1):44. doi: 10.1186/s13073-017-0439-8. Review.

9.

Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients.

van Meir H, Nout RA, Welters MJ, Loof NM, de Kam ML, van Ham JJ, Samuels S, Kenter GG, Cohen AF, Melief CJ, Burggraaf J, van Poelgeest MI, van der Burg SH.

Oncoimmunology. 2016 Dec 23;6(2):e1267095. doi: 10.1080/2162402X.2016.1267095. eCollection 2017.

10.

Control of immune escaped human papilloma virus is regained after therapeutic vaccination.

Ma W, Melief CJ, van der Burg SH.

Curr Opin Virol. 2017 Apr;23:16-22. doi: 10.1016/j.coviro.2017.02.005. Epub 2017 Mar 7. Review.

11.

Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis.

Ma W, Tummers B, van Esch EM, Goedemans R, Melief CJ, Meyers C, Boer JM, van der Burg SH.

Front Immunol. 2016 Nov 22;7:496. eCollection 2016.

12.

Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells.

Beyranvand Nejad E, van der Sluis TC, van Duikeren S, Yagita H, Janssen GM, van Veelen PA, Melief CJ, van der Burg SH, Arens R.

Cancer Res. 2016 Oct 15;76(20):6017-6029. Epub 2016 Aug 28.

13.

TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.

Zom GG, Welters MJ, Loof NM, Goedemans R, Lougheed S, Valentijn RR, Zandvliet ML, Meeuwenoord NJ, Melief CJ, de Gruijl TD, Van der Marel GA, Filippov DV, Ossendorp F, Van der Burg SH.

Oncotarget. 2016 Oct 11;7(41):67087-67100. doi: 10.18632/oncotarget.11512.

14.

Inflammasome-Dependent Induction of Adaptive NK Cell Memory.

van den Boorn JG, Jakobs C, Hagen C, Renn M, Luiten RM, Melief CJ, Tüting T, Garbi N, Hartmann G, Hornung V.

Immunity. 2016 Jun 21;44(6):1406-21. doi: 10.1016/j.immuni.2016.05.008. Epub 2016 Jun 7.

15.

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.

Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, van Poelgeest MI, Kenter GG, Kroep JR, Burggraaf J, Melief CJ, van der Burg SH.

Sci Transl Med. 2016 Apr 13;8(334):334ra52. doi: 10.1126/scitranslmed.aad8307.

PMID:
27075626
16.

The Human Vaccines Project: A roadmap for cancer vaccine development.

Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, Kvistborg P, Melief C, Mellman I, Palucka AK, Redchenko I, Robins H, Sallusto F, Schenkelberg T, Schoenberger S, Sosman J, Türeci Ö, Van den Eynde B, Koff W, Coukos G.

Sci Transl Med. 2016 Apr 13;8(334):334ps9. doi: 10.1126/scitranslmed.aaf0685. Review.

PMID:
27075624
17.

Vaccines for established cancer: overcoming the challenges posed by immune evasion.

van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ.

Nat Rev Cancer. 2016 Apr;16(4):219-33. doi: 10.1038/nrc.2016.16. Epub 2016 Mar 11. Review.

PMID:
26965076
18.

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.

van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof NM, Berends-van der Meer DM, Löwik MJ, Hamming IL, van Esch EM, Hellebrekers BW, van Beurden M, Schreuder HW, Kagie MJ, Trimbos JB, Fathers LM, Daemen T, Hollema H, Valentijn AR, Oostendorp J, Oude Elberink JH, Fleuren GJ, Bosse T, Kenter GG, Stijnen T, Nijman HW, Melief CJ, van der Burg SH.

Clin Cancer Res. 2016 May 15;22(10):2342-50. doi: 10.1158/1078-0432.CCR-15-2594. Epub 2016 Jan 26.

19.

Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.

Wouters MC, Komdeur FL, Workel HH, Klip HG, Plat A, Kooi NM, Wisman GB, Mourits MJ, Arts HJ, Oonk MH, Yigit R, de Jong S, Melief CJ, Hollema H, Duiker EW, Daemen T, de Bruyn M, Nijman HW.

Clin Cancer Res. 2016 Feb 1;22(3):714-24. doi: 10.1158/1078-0432.CCR-15-1617. Epub 2015 Sep 18.

20.

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.

Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH.

Oncotarget. 2015 Oct 13;6(31):32228-43. doi: 10.18632/oncotarget.4772.

21.

The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansion.

Welten SP, Redeker A, Franken KL, Oduro JD, Ossendorp F, Čičin-Šain L, Melief CJ, Aichele P, Arens R.

Elife. 2015 Aug 11;4. doi: 10.7554/eLife.07486.

22.

Therapeutic cancer vaccines.

Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH.

J Clin Invest. 2015 Sep;125(9):3401-12. doi: 10.1172/JCI80009. Epub 2015 Jul 27. Review.

23.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

24.

Synergy between chemotherapy and cancer vaccination.

van der Sluis TC, van der Burg SH, Melief CJ.

Aging (Albany NY). 2015 Jun;7(6):340-1. No abstract available.

25.

The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation.

Tummers B, Goedemans R, Pelascini LP, Jordanova ES, van Esch EM, Meyers C, Melief CJ, Boer JM, van der Burg SH.

Nat Commun. 2015 Mar 13;6:6537. doi: 10.1038/ncomms7537.

26.

Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques.

Borthwick NJ, Rosario M, Schiffner T, Bowles E, Ahmed T, Liljeström P, Stewart-Jones GE, Drijfhout JW, Melief CJ, Hanke T.

Immun Inflamm Dis. 2015 Jun;3(2):82-93. doi: 10.1002/iid3.52. Epub 2015 Mar 11.

27.

New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer.

van der Sluis TC, van der Burg SH, Arens R, Melief CJ.

Curr Opin Immunol. 2015 Aug;35:9-14. doi: 10.1016/j.coi.2015.05.002. Epub 2015 May 19. Review.

PMID:
26001120
28.

Mutation-specific T cells for immunotherapy of gliomas.

Melief CJ.

N Engl J Med. 2015 May 14;372(20):1956-8. doi: 10.1056/NEJMcibr1501818. No abstract available.

PMID:
25970054
29.

Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression.

van der Sluis TC, Sluijter M, van Duikeren S, West BL, Melief CJ, Arens R, van der Burg SH, van Hall T.

Cancer Immunol Res. 2015 Sep;3(9):1042-51. doi: 10.1158/2326-6066.CIR-15-0052. Epub 2015 Apr 17. Erratum in: Cancer Immunol Res. 2015 Nov;3(11):1289.

30.

Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1.

Mooij P, Koopman G, Drijfhout JW, Nieuwenhuis IG, Beenhakker N, Koestler J, Bogers WM, Wagner R, Esteban M, Pantaleo G, Heeney JL, Jacobs BL, Melief CJ.

J Gen Virol. 2015 Jun;96(Pt 6):1478-83. doi: 10.1099/vir.0.000074. Epub 2015 Feb 9.

PMID:
25667320
31.

Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule.

Zom GG, Filippov DV, van der Marel GA, Overkleeft HS, Melief CJ, Ossendorp F.

Oncoimmunology. 2014 Jul 3;3(7):e947892. eCollection 2014.

32.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

33.

Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death.

van der Sluis TC, van Duikeren S, Huppelschoten S, Jordanova ES, Beyranvand Nejad E, Sloots A, Boon L, Smit VT, Welters MJ, Ossendorp F, van de Water B, Arens R, van der Burg SH, Melief CJ.

Clin Cancer Res. 2015 Feb 15;21(4):781-94. doi: 10.1158/1078-0432.CCR-14-2142. Epub 2014 Dec 12.

34.

Scientific contributions toward successful cancer immunotherapy in The Netherlands.

Melief CJ, Scheper RJ, de Vries IJ.

Immunol Lett. 2014 Dec;162(2 Pt B):121-6. doi: 10.1016/j.imlet.2014.10.012. Epub 2014 Oct 16. Review.

PMID:
25455598
35.

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD.

Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.

36.

Antigen-specific active immunotherapy for ovarian cancer.

Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief CJ, Nijman HW.

Cochrane Database Syst Rev. 2014 Sep 17;(9):CD007287. doi: 10.1002/14651858.CD007287.pub3. Review.

PMID:
25229990
37.

N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2.

Willems MM, Zom GG, Khan S, Meeuwenoord N, Melief CJ, van der Stelt M, Overkleeft HS, Codée JD, van der Marel GA, Ossendorp F, Filippov DV.

J Med Chem. 2014 Aug 14;57(15):6873-8. doi: 10.1021/jm500722p. Epub 2014 Jul 23.

PMID:
25019313
38.

Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates.

Zom GG, Khan S, Britten CM, Sommandas V, Camps MG, Loof NM, Budden CF, Meeuwenoord NJ, Filippov DV, van der Marel GA, Overkleeft HS, Melief CJ, Ossendorp F.

Cancer Immunol Res. 2014 Aug;2(8):756-64. doi: 10.1158/2326-6066.CIR-13-0223. Epub 2014 Apr 21.

39.

CD40-mediated amplification of local immunity by epithelial cells is impaired by HPV.

Tummers B, Goedemans R, Jha V, Meyers C, Melief CJM, van der Burg SH, Boer JM.

J Invest Dermatol. 2014 Dec;134(12):2918-2927. doi: 10.1038/jid.2014.262. Epub 2014 Jun 19.

40.

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.

Tjin EP, Krebbers G, Meijlink KJ, van de Kasteele W, Rosenberg EH, Sanders J, Nederlof PM, van de Wiel BA, Haanen JB, Melief CJ, Vyth-Dreese FA, Luiten RM.

Cancer Immunol Res. 2014 Jun;2(6):538-46. doi: 10.1158/2326-6066.CIR-13-0097. Epub 2014 Mar 10.

41.

IgG-mediated anaphylaxis to a synthetic long peptide vaccine containing a B cell epitope can be avoided by slow-release formulation.

Quakkelaar ED, Fransen MF, van Maren WW, Vaneman J, Loof NM, van Heiningen SH, Verbeek JS, Ossendorp F, Melief CJ.

J Immunol. 2014 Jun 15;192(12):5813-20. doi: 10.4049/jimmunol.1302337. Epub 2014 May 9.

42.

Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.

Fransen MF, Cordfunke RA, Sluijter M, van Steenbergen MJ, Drijfhout JW, Ossendorp F, Hennink WE, Melief CJ.

Vaccine. 2014 Mar 26;32(15):1654-60. doi: 10.1016/j.vaccine.2014.01.056. Epub 2014 Feb 7.

PMID:
24508038
43.

Local immunomodulation for cancer therapy: Providing treatment where needed.

Fransen MF, Ossendorp F, Arens R, Melief CJ.

Oncoimmunology. 2013 Nov 1;2(11):e26493. Epub 2013 Oct 10.

44.

The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.

van Meir H, Kenter GG, Burggraaf J, Kroep JR, Welters MJ, Melief CJ, van der Burg SH, van Poelgeest MI.

Anticancer Agents Med Chem. 2014 Feb;14(2):190-203. Review.

PMID:
24237223
45.

The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.

de Vos van Steenwijk PJ, van Poelgeest MI, Ramwadhdoebe TH, Löwik MJ, Berends-van der Meer DM, van der Minne CE, Loof NM, Stynenbosch LF, Fathers LM, Valentijn AR, Oostendorp J, Osse EM, Fleuren GJ, Nooij L, Kagie MJ, Hellebrekers BW, Melief CJ, Welters MJ, van der Burg SH, Kenter GG.

Cancer Immunol Immunother. 2014 Feb;63(2):147-60. Epub 2013 Nov 15.

PMID:
24233343
46.

DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge.

Koopman G, Beenhakker N, Nieuwenhuis I, Doxiadis G, Mooij P, Drijfhout JW, Koestler J, Hanke T, Fagrouch Z, Verschoor EJ, Bontrop RE, Wagner R, Bogers WM, Melief CJ.

AIDS. 2013 Nov 28;27(18):2841-51. doi: 10.1097/QAD.0000000000000047.

PMID:
24105029
47.

Structured reporting of T cell assay results.

Janetzki S, Hoos A, Melief CJ, Odunsi K, Romero P, Britten CM.

Cancer Immun. 2013 Jul 15;13:13. Print 2013. No abstract available.

48.

The distinct role of T cell costimulation in antiviral immunity.

Welten SP, Melief CJ, Arens R.

Curr Opin Virol. 2013 Aug;3(4):475-82. doi: 10.1016/j.coviro.2013.06.012. Epub 2013 Jul 11. Review.

PMID:
23850168
49.

Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.

Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, Drijfhout JW, Silva AL, Jiskoot W, van Hall T, van Veelen PA, Janssen G, Franken K, Cruz LJ, Tromp A, Oostendorp J, van der Burg SH, Ossendorp F, Melief CJ.

Eur J Immunol. 2013 Oct;43(10):2554-65. doi: 10.1002/eji.201343324. Epub 2013 Aug 5.

50.

Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.

Fransen MF, van der Sluis TC, Ossendorp F, Arens R, Melief CJ.

Clin Cancer Res. 2013 Oct 1;19(19):5381-9. doi: 10.1158/1078-0432.CCR-12-0781. Epub 2013 Jun 20.

Supplemental Content

Loading ...
Support Center